Adcendo

Adcendo is a biotech company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancers. From its funding announcement.

$75M Series CRaised 6 months agoCopenhagen, DenmarkBiotech & PharmaDenmark
Visit website →

In their own words

What Adcendo says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotech company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancers". Source

Market expansionResearch and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Adcendo is today

Adcendo announced a Series C round of $75M on 14 April 2026, led by Jeito Capital.

Latest round
Series C
Amount
$75M
Announced
14 April 2026
Headquarters
Copenhagen, Denmark
Sector
Biotech & Pharma
Growth stage
Series C+
Investors
Also participating
Vida Ventures, BPI France, EIFO, all, TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn B
Relevant leadership
CEO Michael Pehl

Momentum AfterRaise intelligence

AfterRaise Score

48
Steady growth
0 funding signals in the last 90 days
Funding recency
9/40
announced within the last year
Round scale
19/25
round size relative to the market
Funding stage
20/20
Series C
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 14 April 2026
    $75M Series C
    Led by Jeito Capital.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Research programme expansion

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure

Based on the Biotech & Pharma sector, a Series C+ round and the priorities the company itself set out. Not a statement of fact.

Early momentum3 connected signals
  • 14 April 2026$75M Series C announced
  • 14 April 2026Stated priority: market expansion
  • 14 April 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Adcendo is open to

Not yet specified

Adcendo has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Adcendo

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Adcendo?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: the roles and projects you have open. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector